| Chimeric antigen receptor-mediated cell targeting |
2023-8-04 |
2023-9-22 |
|
| Engineered target-specific nucleases |
2023-5-02 |
2023-6-29 |
|
| Compositions for linking dna-binding domains and cleavage domains |
2023-4-27 |
2023-6-22 |
|
| engineered target-specific nucleases |
2023-4-26 |
2023-7-19 |
|
| Modulation of liver genes |
2023-3-31 |
2023-6-13 |
|
| Tau modulators, and methods and compositions for delivery thereof |
2023-3-29 |
2023-6-06 |
|
| Serine recombinase systems for site-specific gene editing |
2023-1-27 |
2023-8-03 |
|
| Methods and compositions for treatment of lysosomal storage diseases |
2023-1-25 |
2023-3-16 |
|
| Novel zinc finger fusion proteins for nucleobase editing |
2022-12-22 |
2023-6-29 |
|
| Methods and compositions for nuclease-mediated targeted integration of … |
2022-12-20 |
2023-6-29 |
|
| Genetic modification of cytokine inducible sh2-containing protein (cish) gene |
2022-11-22 |
2023-8-31 |
|
| Delivery Methods And Compositions For Nuclease-Mediated Genome Engineering |
2022-11-17 |
2022-12-22 |
|
| Methods for use of viral vector constructs for the treatment of fabry disease |
2022-11-03 |
2023-5-11 |
|
| B-cell engineering |
2022-10-28 |
2022-12-27 |
|
| Targeted disruption of t cell and/or hla receptors |
2022-10-21 |
2023-9-21 |
|
| Mog-binding proteins and uses thereof |
2022-9-02 |
2023-3-09 |
|
| Liver-specific constructs, factor viii expression cassettes and methods of use … |
2022-9-01 |
2023-4-20 |
|
| Targeted disruption of t cell and/or hla receptors |
2022-8-31 |
2022-10-27 |
|
| Methods And Compositions For Modification of HLA |
2022-8-04 |
2022-9-01 |
|
| Methods for the treatment of sickle cell disease |
2022-8-03 |
2023-2-09 |
|
| Nuclease-Mediated Regulation Of Gene Expression |
2022-7-06 |
2022-7-28 |
|
| Targeted disruption of mhc cell receptor |
2022-6-24 |
2022-8-19 |
|
| Antigen binders specific for il-23r and uses thereof |
2022-6-24 |
2022-12-29 |
|
| Delivery of target specific nucleases |
2022-6-23 |
2022-8-19 |
|
| Methods and compositions for regulation of transgene expression |
2022-6-07 |
2022-8-01 |
|
| Methods and compositions for treatment of genetic condition |
2022-6-02 |
2022-7-22 |
|
| Novel compositions and methods for producing recombinant aav |
2022-5-26 |
2022-7-01 |
|
| Ciita targeting zinc finger nucleases |
2022-5-24 |
2022-12-01 |
|
| Gene correction of scid-related genes in hematopoietic stem cells and … |
2022-5-20 |
2022-7-14 |
|
| Targeted disruption of t cell receptor |
2022-5-20 |
2022-7-07 |
|
| Generation of engineered regulatory t cells |
2022-5-02 |
2022-7-01 |
|
| Zinc finger protein transcription factors for repressing alpha-synuclein … |
2022-3-30 |
2022-6-01 |
|
| Methods and compositions for treatment of fabry disease |
2022-3-14 |
2022-5-24 |
|
| Methods And Compositions For Nuclease-Mediated Genome Engineering And … |
2022-2-09 |
2022-3-03 |
|
| Methods and compositions for modulating pd1 |
2022-1-28 |
2022-12-15 |
|
| T cell modifying compounds and uses thereof |
2022-1-28 |
2022-12-15 |
|
| Compositions for linking dna-binding domains and cleavage domains |
2022-1-18 |
2022-4-01 |
|
| Separation and quantification of empty and full viral capsid particles |
2022-1-10 |
2022-3-01 |
|
| Improved pharmaceutical compositions containing adeno-associated viral vector |
2021-12-17 |
2022-6-23 |
|
| Chromosome 9 open reading frame 72 gene expression modulators and uses thereof |
2021-11-23 |
2022-1-17 |
|
| Controlled transgene expression in regulatory t cells |
2021-11-15 |
2022-1-01 |
|
| Methods for the treatment of beta-thalassemia |
2021-11-02 |
2021-11-19 |
|
| Generation of cd4+ effector and regulatory t cells from human pluripotent stem … |
2021-10-28 |
2022-5-05 |
|
| Engineering aav |
2021-10-19 |
2021-12-01 |
|
| Methods and compositions for targeted single-stranded cleavage and targeted … |
2021-10-18 |
2022-10-06 |
|
| Methods and compositions for treatment of genetic diseases |
2021-10-15 |
2022-1-06 |
|
| Engineered cleavage half-domains |
2021-10-04 |
2022-5-12 |
|
| Methods of detecting anti-aav antibodies |
2021-10-01 |
2022-4-07 |
|
| Novel zinc finger protein transcription factors for repressing alpha-synuclein … |
2021-10-01 |
2022-8-01 |
|
| Assays for fabry disease treatment |
2021-9-30 |
2023-8-09 |
|
| Zinc finger fusion proteins for nucleobase editing |
2021-9-24 |
2023-7-13 |
|
| Htt repressors and uses thereof |
2021-8-13 |
2021-12-02 |
|
| Compositions and methods for producing recombinant aav |
2021-8-11 |
2021-9-30 |
|
| Method and composition for engineering immunity |
2021-7-27 |
2021-10-21 |
|
| Regulation of gene expression using engineered nucleases |
2021-6-29 |
2021-7-29 |
|
| Methods and compositions for the treatment of fabry disease |
2021-6-27 |
2021-8-31 |
|
| Methods and compositions for expressing phenylalanine hydroxylase |
2021-6-11 |
2021-12-16 |
|
| Dna-binding proteins and uses thereof |
2021-6-11 |
2022-11-10 |
|
| Nuclease-mediated regulation of gene expression |
2021-4-26 |
2021-11-11 |
|
| Targeted treatment of leber congenital amourosis |
2021-4-05 |
2021-7-22 |
|
| Methods and compositions for modulation of tau proteins |
2021-4-01 |
2021-5-31 |
|
| Engineered genetic modulators |
2021-3-31 |
2021-5-31 |
|
| Programmed cell death 1 (pd1) specific nucleases |
2021-3-11 |
2021-4-29 |
|
| Methods and compositions for genome engineering |
2021-3-01 |
2021-6-24 |
|
| Engineered target specific base editors |
2021-2-18 |
2021-4-29 |
|
| New car constructs comprising tnfr2 domains |
2021-2-07 |
2021-3-25 |
|
| Improved clinical parameters by expression of factor viii |
2021-1-26 |
2021-3-01 |
|
| Zinc finger protein transcription factors for repressing tau expression |
2021-1-22 |
2021-7-29 |
|
| Method of inactivating a glucocorticoid receptor gene in an isolated cell |
2020-12-18 |
2021-4-08 |
|
| Delivery methods and compositions for nuclease-mediated genome engineering |
2020-12-17 |
2021-3-25 |
|
| Methods and compositions for treating Huntington's Disease |
2020-11-16 |
2023-8-15 |
2023-8-15 |
| Methods and compositions for modification of a hla locus |
2020-11-06 |
2021-2-25 |
|
| Compositions and methods for genome engineering |
2020-10-30 |
2021-8-16 |
|
| Fad3 performance locus and corresponding target site specific binding protein … |
2020-10-30 |
2021-3-04 |
|
| Gin recombinase variants |
2020-10-30 |
2021-5-06 |
|
| Chimeric antigen receptor specific for interleukin-23 receptor |
2020-10-15 |
2021-4-22 |
|
| Chimeric antigen receptor specific for interleukin-23 receptor |
2020-10-11 |
2020-11-30 |
|
| ZINC FINGER PROTEIN TRANSCRIPTION FACTORS FOR REPRESSION OF a-SYNUCLEIN … |
2020-10-02 |
2022-2-02 |
|
| Zinc finger protein transcription factor for prion disease treatment |
2020-10-02 |
2022-7-08 |
|
| Compositions for linking dna-binding domains and cleavage domains |
2020-9-28 |
2021-1-14 |
|
| Controlled expression of chimeric antigen receptors in t cells |
2020-8-07 |
2021-2-18 |
|
| Methods and compositions for treatment of a beta thalessemia |
2020-7-01 |
2020-10-16 |
|
| Methods and compositions for integration of exogenous sequence into genome of … |
2020-6-17 |
2020-11-05 |
|
| Methods and compositions for targeted cleavage and recombination |
2020-4-29 |
2020-9-24 |
|
| Targeted deletion of cellular dna sequences |
2020-4-27 |
2020-9-17 |
|
| Methods and compositions for the treatment of rare diseases |
2020-4-13 |
2020-5-31 |
|
| Methods and compositions for the treatment of lysosomal storage diseases |
2020-4-07 |
2020-7-23 |
|
| Methods and compositions for increasing rna activity in a cell |
2020-4-03 |
2020-10-08 |
|
| Novel anti-hla-a2 antibodies and uses thereof |
2020-3-18 |
2020-5-31 |
|
| Fad2 performance loci and corresponding target site specific binding proteins … |
2020-2-18 |
2020-7-27 |
|
| Compositions for linking zinc finger modules |
2020-2-14 |
2020-5-29 |
|
| Chimeric antigen receptor mediated cell targeting |
2020-1-28 |
2020-3-31 |
|
| Htt repressors and uses thereof |
2020-1-15 |
2023-1-18 |
|
| Identification of molecules for inhibition of nk-mediated cell killing |
2019-11-06 |
2020-5-14 |
|
| Method for the treatment of mucopolysaccharidosis type ii |
2019-8-07 |
2022-6-01 |
|
| Method for the treatment of mucopolysaccharidosis type i |
2019-8-07 |
2020-8-13 |
|
| Enzymatic assays for quantifying therapy in subjects with mucopolysaccharidosis … |
2019-8-07 |
2020-3-05 |
|
| Enzyme assay to quantify treatment in subjects with mucopolysaccharidosis type … |
2019-8-07 |
2022-2-07 |
|
| Targeted modification of malate dehydrogenase |
2019-7-02 |
2021-8-10 |
2021-8-10 |
| Delivery of target specific nucleases |
2019-5-15 |
2019-12-05 |
|